Avacta Group (LSE:AVCT)

Avacta is an early-stage biotech firm specialising in the fields of diagnostics and therapeutics. Its diagnostics division created a proprietary platform called Affimer. It consists of a portfolio of reagent proteins that can be used to detect specific infections within a given sample. Traditionally this process is achieved using antibodies. However, manufacturing antibodies is a complex, time-consuming process that Affimer reagents don’t have to go through. In 2020, Avacta leveraged its Affimer platform to create Covid-19 lateral flow tests. This was the catalyst behind the AVCT share price spike that year. On the therapeutics side of the business, the company is currently testing its flagship AVA6000 chemotherapy drug in clinical trials. This treatment is being developed with the group’s second chemical platform called pre|CISION. Unlike existing chemotherapy treatments, AVA6000 is highly targeted, resulting in less healthy cells being caught in the crossfire, and reducing the severity of side effects.

98.75p -6.25p (-6%) Monday, 4 July 2022 at 16:30:00 British Summer Time


Last updated 04-07-2022, 04:30:00pm BST
Current Price 98.75p
Today's Change -6.25p (-6%)
Close Price 98.75p
Open Price 105.00p
Bid 0.00p
Ask 0.00p
Day Range 96.00p - 105.00p
Year Range 38.00p - 182.00p
Volume 687,681
Average Volume 1,323,440
Market Cap 26,259,123,800.00p
EPS (ttm) -10.55p

Frequently Asked Questions

Avacta was listed on the London Stock Exchange Alternative Investment Market in October 2003 through a reverse takeover. The split-adjusted floating price was 5,250p.

No. According to the 2020 annual report, Avacta does not pay dividends to shareholders, nor has it proposed to do so in the future.